Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis

Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis

BackgroundIn the first-line treatment of advanced non-small cell lung cancer (NSCLC), for those patients with negative PD-L1 expression, which treatment strategy has the better efficacy and safety between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors (ICIs) is still...

Full description

Bibliographic Details
Main Authors: Jiaqi Li, Yingjie Chen, Fan Hu, Huiping Qiang, Qing Chang, Jialin Qian, Yinchen Shen, Yong Cai, Tianqing Chu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer (NSCLC)
immune checkpoint inhibitors (ICIs)
programmed cell death ligand-1 (PD-L1)
negative PD-L1 expression
antiangiogenic therapy
combination
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1001503/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1001503/full

Similar Items